Clinigen Group, the global pharmaceutical and services group, has been notified by Peter George that he intends to step down as chief executive officer on November 11, 2016. He will continue as a non-executive director.

Shaun Chilton, who has been deputy CEO since July 2015 and before that chief operating officer for over three years, will become CEO on that date.

Separately Robin Sibson, who has served as non-executive director since 2015 and before that as the group’s chief financial officer, has notified the board that he intends to retire from the board in November.

Peter Allen, chairman, said, “Peter has done a tremendous job developing and growing Clinigen over the last six years. 

“He built the business from a small private company to its current position as a leading global pharmaceutical products and services business with a market capitalization of some £800 million. He led the IPO four years ago and the two substantial transformational acquisitions over the last 18 months.

“The board looks forward to working with Shaun. He has held a number of senior roles in Clinigen over the last four years and been closely involved in its development. He has the international industry knowledge, expertise and leadership skills to take this business forward. 

Shaun Chilton, CEO-designate said, “I am delighted to have the opportunity to lead Clinigen. We have been building the Group’s infrastructure, capabilities, IP and geographical footprint over the last four years, creating a unique business model with a top quality management team.

“Our focus now is to drive sustainable growth by capitalizing on our market leading positions in clinical trial services and unlicensed medicines and continuing to expand our portfolio of specialty pharmaceuticals.”